# Evidence: peptide-enhancer co-release

Parent: — · class: transport and absorption · names merged here: co-localization of peptide and permeation enhancer; peptide–enhancer co-release

2 papers measured or used it, 0 only mentioned it (of 207 kept papers). Papers in year order; each section heading ends with the paper's category / subcategory. Generated by tools/build_evidence.py from registry/concepts.csv and the cards; do not edit.

## 2025 Bapat — Modification of Peptide and Permeation Enhancer In Vitro Release Rates by Dispersion with a Gel-Forming Polymer · Peptide permeability / Peptide permeability

[2025-bapat-peptide-permeation-enhancer-pvpva-synchronous-release](../../../cards/2025-bapat-peptide-permeation-enhancer-pvpva-synchronous-release/paper.html) · Peptide permeability / Peptide permeability · used · as: co-localization of peptide and permeation enhancer

| id | kind | content | locator |
|---|---|---|---|
| C6 | claim, generalisation, authors: "may help"; "may improve" | Including a gel-forming polymer may help synchronize the release of a hydrophilic peptide and an enhancer, which in turn may improve co-localization at the epithelial membrane [rests on: R2, R5] | p.1003 |
| C8 | claim, prior hypothesis, authors: "it is known"; "are considered important" | Enhancers act by mechanisms that include membrane fluidization and tight-junction disruption and ideally act rapidly and reversibly; high local enhancer concentrations, enhancer effectiveness depending strongly on concentration, and co-localization of peptide and enhancer at the absorption site are needed, with a short absorption window after the enhancer acts [rests on: cited: refs 7-33, 8, 11, 12, 13, 23, 28, 29, 35-44, 53-64] | p.1004-1005, p.1012 |
| C10 | claim, prior hypothesis, authors: asserted; "potentially" | Co-localization of peptide and enhancer is hard to achieve with a solid oral system, especially for the small intestine; gastric conditions, dilution and motility hinder target concentrations, and a peptide and enhancer of different solubilities will dissolve at different rates, potentially impairing co-localization [rests on: argument only; cited: refs 16, 17, 37, 44, 57, 60, 65-70] | p.1005, p.1012 |

## 2025 Fagan — Impact of Permeation Enhancers on the Release of Insulin from Tablets in Biorelevant Media · Peptide permeability / Peptide permeability

[2025-fagan-permeation-enhancers-insulin-minitablet-biorelevant-media](../../../cards/2025-fagan-permeation-enhancers-insulin-minitablet-biorelevant-media/paper.html) · Peptide permeability / Peptide permeability · measured · as: peptide–enhancer co-release

| id | kind | content | locator |
|---|---|---|---|
| R20 | record, measured | time to maximum release — P4, all media — insulin about 30 min in every medium; C10 and SNAC about 15 min in the results section, and 10 min for C10 and 20 min for SNAC in the discussion | text pp. 4003 and 4006 |
| C44 | claim, conclusion, authors: asserted | insulin release was slower than enhancer release, so peptide and enhancer leave the tablet at staggered times [rests on: R20] | text pp. 4006 and 4007 |
| C45 | claim, generalisation, authors: would likely | this staggered release would likely give incongruous presentation at the epithelium and suboptimal enhancement of insulin permeability [rests on: R20] | text p. 4006 |
| C46 | claim, recommendation, authors: should be placed; may prove beneficial | research should improve the corelease of peptide and enhancer, for example by slowing enhancer dissolution or speeding insulin dissolution [rests on: R20] | text p. 4007 |